Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Kathleen SebeliusDirector | HumacyteHUMA | Open-market buy | 05/19 | 05/20 | 56,818 sh | $0.88 | $49,999.84 | +62.3% |
Michael T. ConstantinoDirector | HumacyteHUMA | Open-market buy | 05/18 | 05/20 | 11,000 sh | $0.89 | $9,790 | +33.4% |
Dale A. SanderCFO and Chief Corp. Dev. Off | HumacyteHUMA | Open-market sale10b5-1 plan | 05/18 | 05/20 | 45,887 sh | $0.90 | $41,298.3 | −14.7% |
Shamik J. ParikhChief Medical Officer | HumacyteHUMA | Open-market sale10b5-1 plan | 05/18 | 05/20 | 45,887 sh | $0.90 | $41,298.3 | −14.4% |
HumacyteHUMA | Open-market sale | 25/08/18–25/08/20 | 25/08/20 | 2,241,045 sh3 trades | $1.67avg. | $3,733,191.1 | −100.0% | |
HumacyteHUMA | Open-market sale | 25/08/18–25/08/20 | 25/08/20 | 2,241,045 sh3 trades | $1.67avg. | $3,733,191.1 | −100.0% | |
William John ScheesseleChief Commercial Officer | HumacyteHUMA | Open-market buy | 25/04/14 | 25/04/15 | 6,493 sh | $1.54 | $9,999.22 | +41.8% |
Dale A. SanderCFO and Chief Corp. Deve. Off | HumacyteHUMA | Open-market buy | 25/04/10 | 25/04/14 | 20,000 sh | $1.53 | $30,600 | +97.1% |
Shamik J. ParikhChief Medical Officer | HumacyteHUMA | Open-market buy | 25/04/10 | 25/04/14 | 7,500 sh | $1.55 | $11,625 | No record |
Kathleen SebeliusDirector | HumacyteHUMA | Open-market buy | 25/04/08 | 25/04/08 | 50,000 sh | $1.32 | $66,000 | +121.3% |
Charles Bruce GreenDirector | HumacyteHUMA | Open-market buy | 25/04/08 | 25/04/08 | 6,000 sh | $1.29 | $7,740 | +250.0% |
Michael T. ConstantinoDirector | HumacyteHUMA | Open-market buy | 25/04/07 | 25/04/08 | 16,000 sh | $1.26 | $20,160 | +94.4% |
Michael T. ConstantinoDirector | HumacyteHUMA | Open-market buy | 24/12/04 | 24/12/04 | 4,600 sh | $4.39 | $20,194 | +37.2% |
Brady W. DouganDirector | HumacyteHUMA | Open-market buy | 24/11/19 | 24/11/21 | 1,797 sh | $4.44 | $7,978.68 | +0.7% |
Laura E. NiklasonPresident, CEO and Director | HumacyteHUMA | Open-market buy | 24/11/19 | 24/11/21 | 1,797 sh | $4.44 | $7,978.68 | +0.7% |
HumacyteHUMA | Open-market sale | 24/11/18–24/11/20 | 24/11/20 | 1,500,000 sh3 trades | $4.40avg. | $6,606,799.34 | −46.4% | |
HumacyteHUMA | Open-market sale | 24/11/18–24/11/20 | 24/11/20 | 1,500,000 sh3 trades | $4.40avg. | $6,606,799.34 | −46.4% | |
HumacyteHUMA | Open-market sale | 24/09/10 | 24/09/11 | 5,182 sh2 trades | $5.40avg. | $28,003.66 | −11.2% | |
HumacyteHUMA | Open-market sale | 24/09/09–24/09/10 | 24/09/11 | 446,378 sh2 trades | $5.30avg. | $2,364,520.7 | −12.1% | |
HumacyteHUMA | Open-market sale | 24/09/09–24/09/10 | 24/09/11 | 446,378 sh2 trades | $5.30avg. | $2,364,520.7 | −12.1% |